Sotatercept improves functional class and hemodynamics in SSc-PAH patient with PVOD/PCH features
Background
Patients with Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) often face a poor prognosis, particularly when complicated by features of Pulmonary Veno-Occlusive Disease/Pulmonary Capillary Hemangiomatosis (PVOD/PCH). This subgroup presents unique challenges, as traditional PAH therapies, such as parenteral prostacyclins, carry a significant risk of inducing pulmonary edema due to the underlying veno-occlusive pathology. Identifying safe and effective treatment options for these high-risk patients remains a critical unmet need, as current standard-of-care often falls short.
Study Design
This case report describes a 53-year-old woman with SSc-PAH and PVOD/PCH features, who presented with severe exertional desaturation and a markedly reduced diffusing capacity (%DLCO 30%). Despite receiving triple oral therapy, her pulmonary hypertension progressed, with mean pulmonary arterial pressure (mPAP) increasing from 34 to 51 mmHg. Sotatercept was initiated due to concerns about the risk of pulmonary edema with prostacyclin therapy. Treatment was intermittently interrupted due to hemoglobin elevation. Primary endpoints included World Health Organization (WHO) functional class, 6-minute walk distance (6MWD), brain natriuretic peptide (BNP) levels, and mPAP.
Results
Following the initiation of sotatercept, the patient demonstrated significant clinical and hemodynamic improvements. Her WHO functional class improved from III to II. The 6-minute walk distance (6MWD) increased substantially from 217 m to 301 m, representing a 38.7% improvement. Brain natriuretic peptide (BNP) levels, a key biomarker for cardiac strain, decreased from 206.4 pg/mL to 52.8 pg/mL, a reduction of approximately 74.4%. Hemodynamic assessment revealed a decrease in mean pulmonary arterial pressure (mPAP) from 51 mmHg to 45 mmHg. Importantly, these improvements were achieved without any episodes of pulmonary edema, a critical concern given the patient's PVOD/PCH features. > The patient's 6-minute walk distance increased by 84 meters, from 217 m to 301 m, demonstrating a significant improvement in exercise capacity.
Key Findings
- Patient's WHO functional class improved from III to II.
- 6-minute walk distance increased from 217 m to 301 m.
- Brain natriuretic peptide (BNP) levels decreased from 206.4 pg/mL to 52.8 pg/mL.
- Mean pulmonary arterial pressure (mPAP) decreased from 51 mmHg to 45 mmHg.
- Improvements observed without inducing pulmonary edema, despite PVOD/PCH features.
Why It Matters
This case report highlights sotatercept's potential as a therapeutic option for a challenging subgroup of SSc-PAH patients with PVOD/PCH features, who are often excluded from or poorly responsive to conventional therapies. For individuals at high risk of pulmonary edema from prostacyclins, sotatercept offers a novel mechanism targeting Activin receptor type IIA (ActRIIA) signaling, which may remodel pulmonary vasculature without exacerbating veno-occlusive pathology. This suggests a critical expansion of treatment strategies, potentially allowing clinicians to address a previously intractable patient population. While a single case, it provides early signal for future trials, moving us closer to a usable protocol for this specific, high-risk demographic.
sotatercept
pulmonary hypertension
pah
systemic sclerosis
pvod
pch